Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
Sanara MedTech (Nasdaq: SMTI) will report first quarter 2026 financial results on May 12, 2026 before U.S. markets open and will host a conference call and webcast at 8:00 a.m. ET.
Rhea-AI Summary
Sanara MedTech (Nasdaq: SMTI) will report first quarter 2026 financial results on May 12, 2026 before U.S. markets open and will host a conference call and webcast at 8:00 a.m. ET.
The call will cover the quarter ended March 31, 2026, include a Q&A, offer telephonic and online replays, and the webcast will be available via the company investor relations site.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SMTI
On Apr 14, the day this news came out, SMTI closed 5.17% above the previous close.
Data tracked by StockTitan Argus for the Apr 14 session.
Key Figures
- Earnings release date
- May 12, 2026
- First quarter 2026 financial results release before U.S. markets open
- Conference call time
- 8:00 a.m. ET
- Start time of Q1 2026 results call on May 12, 2026
- Toll-free dial-in
- 888-506-0062
- Primary U.S. number for the Q1 2026 earnings conference call
- International dial-in
- 973-528-0011
- International access number for the Q1 2026 earnings call
- Access code
- 931324
- Access code required to join the live Q1 2026 conference call
- Replay deadline
- May 26, 2026
- Date through which the telephonic replay will be available
- Replay passcode
- 53818
- Passcode required to access the telephonic replay
- Webcast replay window
- ≈1 year
- Approximate duration the online replay will be available
Previous Earnings date Reports
-
Announced timing and call details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open.
The Company will host a conference call and webcast on May 12, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2026 and hold a question and answer session at the end of the call. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 931324. A telephonic replay of the conference call will be available through Tuesday, May 26, 2026, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 53818.
A live webcast of Sanara’s conference call is accessible by clicking here and will be made available under the ”Events” section of the Company’s Investor Relations website, https://ir.sanaramedtech.com/. An online replay will be available for approximately one year following the conclusion of the live broadcast.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products to surgeons at hospitals and surgical centers. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.